Therapeutic efficacy and clinical acceptability of fusafungine in follicular pharyngitis.
Eighty-one patients suffering from follicular pharyngitis were treated for 7 days in a double-blind, multicentre controlled study of fusafungine versus placebo. Evaluations were performed at inclusion, after 7 days of treatment, and 3 weeks after the end of the treatment. The effects of the pharyngitis on day-to-day life, changes in symptoms, morphological changes of lesions, and general changes observed by the investigator and expressed by the patient were the parameters evaluated at each visit. Results confirmed the efficacy of fusafungine in the treatment of local and symptomatic manifestations of follicular pharyngitis. Effects of follicular pharyngitis on day-to-day life decreased after 7 days of treatment and the differences between the treatment group and the placebo group was close to significance in favour of fusafungine. For the majority of symptoms, the percentage of patients who did not display the symptoms at D7 was greater in the fusafungine group. Postnasal drip decreased significantly in the fusafungine group. The investigators' and patients' judgement was also in favour of the fusafungine treatment. These improvements were confirmed at least 3 weeks after the end of the treatment.
Pandraud
L
L
Centre Hospitalier de Saint-Cloud, France. apandraud@aol.com
D000280:Administration, Inhalation; D000281:Administration, Intranasal; D000328:Adult; D000336:Aerosols / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D047630:Depsipeptides; D004311:Double-Blind Method; D005260:Female; D005670:Fusarium; D006801:Humans; D008297:Male; D008875:Middle Aged; D010612:Pharyngitis / Q000188:drug therapy*; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D000336:Aerosols; D000900:Anti-Bacterial Agents; D047630:Depsipeptides; C014001:fusafungin